Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most non-safety claims (indications, IL-17A mechanism, route) appear consistent with typical COSENTYX labeling, but several safety claims are not fully supportable from the provided label excerpts (especially the specificity of “most common” adverse reactions and the exact duration/risk thresholds for infections and skin cancer). Multiple claims about seriousness/frequency and specific adverse reaction labels are unsupported or partially supported.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is used to treat psoriasis.
Supported indirectly by indication labeling not included in the excerpts; however mechanism/route and safety sections suggest alignment. No direct indication section text provided in the supplied excerpts.
Cosentyx (secukinumab) is used to treat psoriatic arthritis.
No direct indication text provided in excerpts; mechanism/route and warnings sections are consistent with COSENTYX labeling but not provable from given excerpts.
Cosentyx (secukinumab) is used to treat ankylosing spondylitis.
No direct indication text provided in excerpts; mechanism/route and warnings sections are consistent with COSENTYX labeling but not provable from given excerpts.
Cosentyx is a biologic medication that blocks the action of interleukin-17A (IL-17A).
Supported by the provided excerpts referencing IL-17 inhibitors (Section 5.1) and COSENTYX pharmacology context (no explicit wording “blocks IL-17A” provided, but IL-17 inhibitor context supports the claim).
Cosentyx is administered through subcutaneous injections.
Supported: “UnoReady pen, Sensoready pen, and prefilled syringes are for subcutaneous use only.” (Section 2.2).
Less common but serious side effects of Cosentyx can include hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis).
Partially supported: anaphylaxis and angioedema are supported (Sections 4, 5.2, 6.2). Stevens-Johnson syndrome and toxic epidermal necrolysis are not explicitly present in the provided excerpts.
Unsupported Statements
The most common side effects of Cosentyx include injection site reactions (redness, swelling, itching, or pain at the injection site).
The provided excerpts (Sections 4, 5.1-5.7, 6.1-6.2) do not list frequency categories such as “most common” or specific injection-site symptom breakdown.
The most common side effects of Cosentyx include upper respiratory tract infections (sinusitis, bronchitis, and pneumonia).
The excerpts state increased infection risk and mention infections generally (Section 5.1, Section 6.1), but do not support “most common” nor the specific grouping of sinusitis/bronchitis/pneumonia as most common.
The most common side effects of Cosentyx include nasopharyngitis (a common cold).
No nasopharyngitis/common cold frequency or labeling is present in the provided excerpts.
The most common side effects of Cosentyx include headache.
Headache is not present in the provided excerpts under adverse reactions with frequency.
The most common side effects of Cosentyx include fatigue.
Fatigue is not present in the provided excerpts with frequency.
The most common side effects of Cosentyx include musculoskeletal pain (back pain, neck pain, and joint pain).
Musculoskeletal pain/back pain/neck pain/joint pain are not present in the provided excerpts with frequency.
Less common but serious side effects of Cosentyx can include serious infections (tuberculosis, bacterial sepsis, and fungal infections).
The excerpts support serious opportunistic infections including bacterial/viral/fungal (Section 5.1, 6.2) and TB evaluation/active TB risk (Section 5.3), but do not explicitly support “bacterial sepsis” phrased as an adverse reaction category, nor the “less common” frequency.
Less common but serious side effects of Cosentyx can include malignancies (skin cancer, lymphoma, and other types of cancer).
The provided excerpts do not mention malignancies/cancer risk, skin cancer, or lymphoma.
Patients taking Cosentyx for more than 12 months had a higher risk of developing serious infections.
The provided excerpts describe infection risk and seriousness, but do not provide duration-based thresholds (e.g., >12 months) or a specific temporal risk increase.
Patients taking Cosentyx for more than 24 months had a higher risk of developing skin cancer.
The provided excerpts do not mention skin cancer or malignancy risk, and do not provide duration-based thresholds (e.g., >24 months).
Cosentyx is administered through subcutaneous injections.
Not unsupported; this is supported. (Included here only if needing route precision: the claim omits that IV administration exists for certain adult indications per label excerpt 2.2, but the claim is not directly contradicted.)
Less common but serious side effects of Cosentyx can include hypersensitivity reactions (anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis).
Anaphylaxis is supported (Sections 4, 5.2, 6.2) but Stevens-Johnson syndrome and toxic epidermal necrolysis are not supported by the provided excerpts.
Contradictions
Important Omissions
Monitoring and stopping guidance for serious infection (evaluate/monitor closely; discontinue until resolved).
Importance:
Moderate
Pre-treatment TB evaluation and avoidance of active TB; latent TB treatment prior to initiation.
Importance:
Moderate
Latex risk for Sensoready pen/prefilled syringes (natural rubber latex) in latex-sensitive individuals.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related claims specify frequency (“most common” / “less common”) and particular severe outcomes (malignancies; bacterial sepsis; SJS/TEN) and duration-threshold risks that are not supported by the provided excerpts. If used clinically, these could misinform risk perception; however, core safety themes like increased infection risk, serious hypersensitivity, and TB evaluation are present in the label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Safety frequency/category and specificity claims (e.g., “most common” adverse reactions; malignancies; bacterial sepsis; SJS/TEN; >12 months serious infection and >24 months skin cancer) are not supported by the provided label excerpts.
Suggested Improvement
Restrict safety statements to what is explicitly supported in the supplied excerpts (e.g., infections including serious opportunistic/fatal infections; TB evaluation; anaphylaxis/angioedema; latex warning). Remove or qualify unsupported frequency labels and unsupported specific outcomes/duration thresholds unless directly supported by the label sections not provided.